Date:11/10/2009

====== =========== ========== =========== * The following pro forma adjustments were made solely as supplemental financial information to help investors and the financial community make meaningful comparisons of operating results from one financial period to another. 1. Non-cash stock based compensation is excluded. 2. The non-cash change in the fair market of derivative liabilities is excluded. This is the effect of non-cash charges associated with the treatment of the value of certain derivative securities under newly- adopted EITF 07-05, which effects can vary substantially each quarter along with changes to the price of the underlying common stock during the quarter. 3. Debt discount (non cash) was added back to reflect the actual amount of debt owed at the end of each period reported. 4. Non cash derivative liabilities were excluded. 5. Non cash charges for the amortization of the debt discount were removed. * Note: Additional pro forma information is included. The Company presents this information to investors as an additional tool for evaluating the Company's financial results in a manner that reflects ongoing operations and facilitates comparisons with operating results from prior periods. The presentation of this additional non-GAAP information is intended to provide investors with additional incremental tools for their review of the Company's results and is not meant to be considered in isolation or as a substitute for the actual net income and balance sheet information prepared and provided in accordance with GAAP.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

SOURCE Ca
'/>"/>

SOURCE Cardium Therapeutics Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems